復旦張江(01349.HK)上半年純利升125.20%至6548.5萬元
格隆匯8月11日丨復旦張江(01349.HK)公佈,截至2021年6月30日止6個月,公司實現收入人民幣3.99億元,同比增長69.36%;公司股東應占期內利潤人民幣6548.5萬元,同比增長125.20%;每股盈利人民幣0.0628元。
隨着國內疫情基本得到控制,藥品流通及醫院患者就診顯着恢復,集團各醫藥產品的出貨量及藥品終端使用量亦開始穩步恢復。報吿期內,公司實現營業收入人民幣3.99億元,較上年同比上升69.36%。治療以尖鋭濕疣為代表的皮膚HPV感染性疾病和增生性疾病的艾拉®、治療腫瘤的裏葆多?及治療鮮紅斑痣的復美達®作為集團最重要的三大產品,對集團銷售醫藥及診斷產品收入貢獻達到99.6%。
研發方面,集團堅持基於基因工程技術、光動力技術、納米技術和口服固體制劑技術平台的藥物開發方向,繼續採用針對選定藥物拓展新的臨牀適應症以及針對選定疾病繼續拓展新的藥物並設計出新的治療方案的研究模式。同時,集團在分子靶向、免疫治療、基因治療與基因編輯等領域進行了探索與開拓,以期成為新的研發方向。報吿期內,集團綜合考慮研發資源、研發風險及研發週期後,繼續將藥物開發集中在腫瘤、皮膚和自身免疫等疾病領域,擴大和強化了產業化藥物數量和進度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.